▲ Peaking
Business
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
5sources
5articles
3velocity
+0%since first seen
2h agofirst detected
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (5)
- Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped BioSpace · 10h ago
- Sanofi nixes Kymab-originated OX40L antibody in eczema Endpoints News · 10h ago
- Sanofi shelves amlitelimab in atopic dermatitis after pipeline review FirstWord Pharma · 10h ago
- Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO WSJ · 10h ago
- Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout Fierce Biotech · 10h ago
Related trends
▲ Peaking
Business
Elon Musk Melts Down Over Perfectly Normal Questions in Wild New Interview
▲ Peaking
Business
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
▲ Peaking
Business
Yang Zhilin, the rock star founder behind China’s Moonshot AI
▲ Peaking
Business
This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly
▲ Peaking
Business
Why Trump is facing his biggest danger from rising oil prices since the war began
▲ Peaking
Business